Xencor, Inc. (NASDAQ:XNCR) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd increased its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 191.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 54,209 shares of the biopharmaceutical company's stock after buying an additional 35,627 shares during the period. XTX Topco Ltd owned about 0.08% of Xencor worth $577,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in XNCR. Sterling Capital Management LLC raised its stake in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,040 shares in the last quarter. New York State Teachers Retirement System grew its holdings in Xencor by 2.1% in the first quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company's stock worth $631,000 after purchasing an additional 1,200 shares during the last quarter. Summit Investment Advisors Inc. increased its position in shares of Xencor by 22.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock worth $162,000 after purchasing an additional 1,282 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Xencor during the 4th quarter valued at $34,000. Finally, Exchange Traded Concepts LLC boosted its position in shares of Xencor by 23.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,814 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 1,896 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. William Blair started coverage on shares of Xencor in a report on Monday, April 21st. They set an "outperform" rating on the stock. Wedbush cut their price objective on shares of Xencor from $31.00 to $26.00 and set an "outperform" rating on the stock in a research note on Thursday. Barclays decreased their price target on Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Finally, Wells Fargo & Company lowered their target price on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research note on Thursday. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Xencor has a consensus rating of "Moderate Buy" and an average price target of $26.43.

Insider Transactions at Xencor

In other news, Director Richard J. Ranieri sold 2,993 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director owned 19,183 shares in the company, valued at $176,867.26. This trade represents a 13.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total value of $27,595.46. Following the sale, the director directly owned 19,183 shares of the company's stock, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,194 shares of company stock worth $103,209 in the last quarter. Company insiders own 4.76% of the company's stock.

Xencor Price Performance

Shares of NASDAQ:XNCR traded down $0.09 during trading on Friday, reaching $7.23. The stock had a trading volume of 872,504 shares, compared to its average volume of 765,719. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89. Xencor, Inc. has a 1-year low of $7.07 and a 1-year high of $27.24. The stock has a market cap of $514.56 million, a PE ratio of -3.01 and a beta of 0.89. The business has a fifty day moving average price of $8.67 and a 200-day moving average price of $11.00.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.37. The company had revenue of $43.61 million for the quarter, compared to analysts' expectations of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.24%. The firm's quarterly revenue was up 82.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.07) EPS. On average, equities analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.